Table 2 Adverse events during the follow-up period.

From: Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration

Ocular AE

 ~ 6 W

6–12 W

12–24 W

Any IOI (male/female)

5 (2/3)

3 (3/0)

4 (3/1)

RV

0

0

0

RO

0

0

0

Systemic AE

  Brain infarction

1

0

0

  1. AE Adverse event, IOI Intraocular inflammation, RV Retinal vasculitis, RO Retinal vascular occlusion.
Back to article page